PTD4-apoptin protein and dacarbazine show a synergistic antitumor effect on B16-F1 melanoma in vitro and in vivo

European Journal of Pharmacology

Volumn 654, Issue 1, 2011, Pages 17-25

  Jin, Jia Lu ^a   Gong, Jing ^a   Yin, Tie Jun ^b   Lu, Yan Jun ^a   Xia, Jing Jing ^a   Xie, Yu Yuan ^a   Di, Yong ^a   He, Lei ^a   Guo, Jian Li ^a   Sun, Jun ^a   Noteborn, Mathieu H M ^a,c   Qu, Shen ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Apoptosis; Combinatorial anticancer therapy; Dacarbazine; Melanoma; PTD4 mediated apoptin protein delivery

Indexed keywords

ANTINEOPLASTIC AGENT; DACARBAZINE; PROTEIN TRANSDUCTION DOMAIN 4 APOPTIN FUSION PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER GROWTH; CANCER INHIBITION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; EMBRYO; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MELANOMA CELL; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CAPSID PROTEINS; CELL LINE; CELL LINE, TUMOR; DACARBAZINE; DRUG SYNERGISM; FEMALE; HUMANS; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; RECOMBINANT FUSION PROTEINS;

EID: 78951480362     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.12.004     Document Type: Article

References (28)

1. S.S. Agarwala Current systemic therapy for metastatic melanoma Expert Rev. Anticancer Ther. 9 2009 587 595
2. C. Backendorf, A.E. Visser, A.G. De Boer, R. Zimmerman, M. Visser, P. Voskamp, Y.H. Zhang, and M.H.M. Noteborn Apoptin: therapeutic potential of an early sensor of carcinogenic transformation Annu. Rev. Pharmacol. 48 2008 143 169
3. C.M. Bagi Targeting of therapeutic agents to bone to treat metastatic cancer Adv. Drug Deliv. Rev. 57 2005 995 1010
4. S.S. Cao, and Y.S. Zhen Potentiation of antimetabolite antitumor activity in vivo by dipyridamole and amphotericin B Cancer Chemother. Pharmacol. 24 1989 181 186
5. A.M. Eggermont, and J.M. Kirkwood Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur. J. Cancer 40 2004 1825 1836
6. C. Garbe, and U. Leiter Melanoma epidemiology and trends Clin. Dermatol. 27 2009 3 9
7. S. Grimm, and M.H.M. Noteborn Anticancer genes: inducers of tumour-specific cell death signaling Trends Mol. Med. 16 2010 88 96
8. A. Hauschild, R. Dummer, S. Ugurel, K.C. Kaehler, F. Egberts, W. Fink, J. Both-Skalsky, B. Laetsch, and D. Schadendorf Combined treatment with pegylated interferon-alpha-2a and dacarbazine in patients with advanced metastatic melanoma: a phase 2 study Cancer 113 2008 1404 1411
9. A. Ho, S.R. Schwarze, S.J. Ermelstein, G. Waksman, and S.F. Dowdy Synthetic protein transduction domains: enhanced transduction potential in vitro and in vivo Cancer Res. 61 2001 474 477
10. B. Kasper, V. D'Hondt, P. Vereecken, and A. Awada Novel treatment strategies for malignant melanoma: a new beginning? Crit. Rev. Oncol. Hematol. 62 2007 16 22
11. H. Lian, N. Jin, X. Li, Z. Mi, J. Zhang, L. Sun, X. Li, H. Zheng, and P. Li Induction of an effective anti-tumor immune response and tumor regression by combined administration of IL-18 and apoptin Cancer Immunol. Immunother. 56 2007 181 192
12. T. Lillehammer, B.O. Engesaeter, L. Prasmickaite, G.M. Maelandsmo, O. Fodstad, and O. Engebraaten Combined treatment with Ad-hTRAIL and dacarbazine or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines J. Gene Med. 9 2007 440 451
13. X.Y. Liu Targeting gene-virotherapy of cancer and its prosperity Cell Res. 16 2006 879 886
14. R.M. MacKie, A. Hauschild, and A.M. Eggermont Epidemiology of invasive cutaneous melanoma Ann. Oncol. 20 Suppl 6 2009 vi1 vi7
15. S. Maddika, F.J. Mendoza, K. Hauff, C.R. Zamzow, T. Paranjothy, and M. Los Cancer-selective therapy of the future: apoptin and its mechanism of action Cancer Biol. Ther. 5 2006 10 19
16. M.H.M. Noteborn Apoptin acts as a tumor-specific killer: potentials for an anti-tumor therapy Cell. Mol. Biol. 51 2005 49 60
17. M.H.M. Noteborn Proteins selectively killing tumor cells Eur. J. Pharmacol. 625 2009 165 173
18. M.H. Noteborn, D. Todd, C.A. Verschueren, H.W. de Gauw, W.L. Curran, S. Veldkamp, A.J. Douglas, M.S. McNulty, A.J. van der Eb, and G. Koch A single chicken anemia virus protein induces apoptosis J. Virol. 68 1994 346 351
19. S.J. Olijslagers, Y.H. Zhang, C. Backendorf, and M.H. Noteborn Additive cytotoxic effect of apoptin and chemotherapeutic agents paclitaxel and etoposide on human tumour cells Basic Clin. Pharmacol. Toxicol. 100 2007 127 131
20. D.J. Peng, J. Sun, Y.Z. Wang, J. Tian, Y.H. Zhang, M.H. Noteborn, and S. Qu Inhibition of hepatocarcinoma by systemic delivery of Apoptin gene to the hepatic asiaglycorprotein receptor Cancer Gene Ther. 14 2007 66 73
21. J.L. Rohn, and M.H. Noteborn The viral death effector apoptin reveals tumor-specific processes Apoptosis 9 2004 315 322
22. J. Sun, Y. Yan, X.T. Wang, X.W. Liu, D.J. Peng, M. Wang, J. Tian, Y.Q. Zong, Y.H. Zhang, M.H. Noteborn, and S. Qu PTD4-apoptin protein therapy inhibits tumor growth in vivo Int. J. Cancer 124 2009 2973 2981
23. V.A. Trinh Current management of metastatic melanoma Am. J. Health Syst. Pharmacol. 65 2008 S3 S8
24. M.M. Van der Eb, A.M. Pietersen, F.M. Speetjens, P.J. Kuppen, C.J. Van de Velde, M.H. Noteborn, and R.C. Hoeben Gene therapy with apoptin induces regression of xenografted human hepatomas Cancer Gene Ther. 9 2002 53 61
25. M. Wolf, H. Eskerski, U. Bauder-Wüst, U. Haberkorn, and M. Eisenhut Alkylating benzamides with melanoma cytotoxicity: experimental chemotherapy in a mouse melanoma model Melanoma Res. 16 2006 487 496
26. S.P. Xu, G.P. Sun, Y.X. Shen, W.R. Peng, H. Wang, and W. Wei Synergistic effect of combining paeonol and cisplatin on apoptotic induction of human hepatoma cell lines Acta Pharmacol. Sin. 28 2007 869 878
27. A.S. Yang, and P.B. Chapman The history and future of chemotherapy for melanoma Hematol. Oncol. Clin. North Am. 23 2009 583 597
28. Y.H. Zhang, S.R. Leliveld, K. Kooistra, C. Molenaar, J.L. Rohn, H.J. Tanke, J.P. Abrahams, and M.H. Noteborn Recombinant Apoptin multimers kill tumor cells but are nontoxic and epitope-shielded in normal-cell-specific fashion Exp. Cell Res. 289 2003 36 46